Skip to main content

Advertisement

Table 3 Effect of various pathway activators on [ 3 H]saquinavir accumulation in microglia

From: Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment

Activator Concentration Saquinavir transport (% control)
   10 ng/ml LPSa Activator alone
TNF-α 10 ng/ml 73 ± 2 98 ± 6
IL-1β 10 ng/ml 77 ± 2 99 ± 2
DEA NONOate 1 μM 61 ± 2 92 ± 5
DEA NONOate 10 μM 61 ± 2 92 ± 4
DEA NONOate 25 μM 61 ± 2 99 ± 6
ET-1 100 nM 61 ± 3 95 ± 2
PMA 1 μM 58 ± 2 94 ± 4
PCN 1 μM 54 ± 2 99 ± 4
PGE2 1 μM 61 ± 3 103 ± 4
  1. DEA NONOate, 2-(N,N-dimethylamino)-diazenolate-2-oxide; ET-1, endothelin-1; IL-1β, interleukin-1-beta; TNF-α, tumor necrosis factor-alpha; PMA, phorbol-12-myristate-13-acetate; PCN, 5-pregnen-3β-ol-20-one-16α-carbonitrile; PGE2, prostaglandin E2. aIn each separate experiment, 10 ng/ml LPS decreased saquinavir accumulation significantly (a P < 0.05, statistically significant from untreated controls).